Biospecimen logistics for clinical trials

01Overview and value chain

Markers: [EC: NACE 52.29 (Other courier activities) | OECD: Bio-pharma | Regulator: FDA (USA), EMA (EU), NMPA (CN)]

Biospecimen logistics for clinical trials is the temperature-controlled, chain-of-custody transport and storage of patient-derived samples — blood, tissue, and cells — between trial sites, central laboratories, and biorepositories. It is governed by GxP, Good Distribution Practice (GDP), and IATA temperature-control regulations, and it is scaling rapidly as cell-and-gene-therapy (CGT) trials and decentralized studies multiply. The segment is consolidating around GDP- and IATA CEIV Pharma-certified courier networks: Marken alone operates across 43 countries with some 1,406 staff and roughly GBP 168.9 million in annual revenue, PCI Pharma Services has committed over $1 billion to expand US and European capacity, and cryogenic storage now reaches −190°C for viable cell assets.

The key directions of biospecimen logistics are:

1. Cold-Chain Courier Networks: GDP- and IATA CEIV Pharma-certified couriers move time-critical, temperature-sensitive biospecimens across borders with validated packaging and real-time monitoring.
2. Cryogenic Storage & Biorepository: Automated cryogenic storage (down to −190°C) preserves viable cells, tissues, and CGT starting material across the research spectrum from discovery to therapeutic products.
3. Decentralized & Direct-to-Patient Trials: Home health visits and mobile phlebotomy shift sample collection closer to the patient, requiring last-mile cold-chain and integrated logistics platforms.
4. Chain-of-Custody Digital Tracking: IoT temperature loggers, barcode/RFID chain-of-custody, and electronic data capture link each sample to its analytical record without loss of identity.

Sectoral value chain

[Collection] ──> [Packaging] ──> [Transport] ──> [Storage / Biorepository]
                              │
                      (Chain of Custody)
                              │
                              ▼
[Trial Data] <─── [Central Lab / Analytics] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Cold-Chain Courier Networks: GDP- and IATA CEIV Pharma-certified transport with validated thermal packaging and real-time temperature monitoring.
• Cryogenic Biorepository: Automated −150°C to −190°C storage for viable cells and CGT starting material.
• Chain-of-Custody Tracking: IoT loggers and barcode/RFID systems that preserve sample identity from draw to data.

02US

The United States leads the market through specialty pharma couriers and biorepository specialists anchored to the world’s largest concentration of clinical trials and CGT developers.

Specialty couriers, CGT logistics, cryogenic storage

• World Courier: A specialty pharma logistics leader advancing cell-and-gene-therapy trial logistics, often in partnership with CROs such as IQVIA.
• Marken: A UPS Healthcare company operating across 43 countries with around 1,406 staff and roughly GBP 168.9 million in revenue, headquartered in Durham, North Carolina.
• Azenta Life Sciences: Provides sample and biological-material storage and automated cryogenic systems (e.g. CryoArc) spanning discovery to clinical trials.

03CN

China’s biospecimen logistics is anchored by large third-party medical-testing networks that combine a national specimen-collection footprint with central-laboratory capacity.

Third-party testing networks, national specimen footprint, central labs

• KingMed Diagnostics: Guangzhou Kingmed Diagnostics Group (603882.SS), one of China’s largest third-party medical-testing and specimen-network operators.
• National footprint: Dense collection and referral networks move biospecimens from hospitals to central labs at provincial scale.
• Clinical-trial uptake: Domestic CRO and pharma growth drives demand for compliant clinical biospecimen handling.

04EU

Europe combines air-freight cold-chain infrastructure with CDMO-linked clinical distribution, expanding capacity to serve cross-border multi-region trials.

Airfreight cold chain, CDMO capacity, cross-border trials

• DHL Medical Express: Operates a growing temperature-controlled airfreight cold-chain network with dedicated capacity and aviation routes for time-critical pharma and biologics.
• PCI Pharma Services: Has committed over $1 billion to expand US and European sterile fill-finish and drug-device capabilities, integrating clinical supply with distribution.
• Regulatory baseline: EU GDP and EMA requirements set a stable compliance framework for cross-border specimen and investigational-product movement.

05Leading companies and research institutes

06Tech stack and innovations

The segment’s stack couples validated thermal packaging, IoT monitoring, and biorepository automation, all wrapped in GxP/GDP data integrity.

1. Cold-Chain Courier Networks:
   • GDP- and IATA CEIV Pharma-certified couriers move samples in validated shippers across controlled ambient, chilled, frozen, and cryogenic ranges.
   • Real-time temperature and location monitoring protects sample integrity across 43-country networks such as Marken’s.
2. Cryogenic Biorepository:
   • Automated cryogenic storage (down to −190°C, e.g. Azenta CryoArc) preserves viable cells and CGT starting material with sample-management software.
   • Enables long-term archive and retrieval for retrospective biomarker and longitudinal analyses.
3. Chain-of-Custody Tracking:
   • IoT loggers, barcode/RFID, and electronic data capture bind each biospecimen to its analytical and consent record end to end.
   • Underpins FDA 21 CFR Part 11 data-integrity expectations and audit-ready trial records.

07Value chains and production pipelines

Industrial pipeline of clinical biospecimen logistics (GDP / IATA CEIV Pharma / 21 CFR Part 11)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Collection             │ ───> │ 2. Packaging              │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Storage / Biorepository│ <─── │ 3. Transport              │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Central Lab / Analytics│ ───> │ 6. Trial Data Linkage     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Collection

Patient biospecimens are drawn and stabilized at trial sites or through in-home visits, labelled with unique identifiers that carry consent and chain-of-custody from the first touchpoint.

Stage 2: Packaging

Specimens are placed in validated temperature-controlled shippers — controlled ambient, chilled, frozen, or cryogenic (dry-shipper) — selected to the sample’s stability profile and transit time.

Stage 3: Transport

GDP- and IATA CEIV Pharma-certified couriers move packaged samples across sites, borders, and central labs with real-time temperature and location monitoring and documented handoffs.

Stage 4: Storage / biorepository

Samples are received into monitored, often automated biorepository space, including cryogenic storage down to −190°C for viable cells and CGT assets, with inventory catalogued for retrieval.

Stage 5: Central lab / analytics

Specimens are queued for testing, omics, and biomarker analysis at central or specialty laboratories, with results bound to each sample’s chain-of-custody identifier.

Stage 6: Trial data linkage

Analytical results are linked back to the electronic trial record under 21 CFR Part 11 data-integrity expectations, closing the loop between patient sample and study outcome and enabling retrospective and longitudinal analyses.